COYA 301
Alternative Names: COYA-301; LD IL-2; Low-dose IL-2Latest Information Update: 13 Feb 2025
At a glance
- Originator ARScience Bio
- Developer Coya Therapeutics
- Class Antidementias; Antiparkinsonians; Cytokines; Interleukins; Neuroprotectants
- Mechanism of Action Interleukin 2 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Alzheimer's disease
- Preclinical Frontotemporal dementia; Parkinson's disease
Most Recent Events
- 06 Feb 2025 Pharmacodynamics data from a phase-II clinical trials in Alzheimer's disease released by Coya Therapeutics
- 29 Oct 2024 Efficacy and adverse events data from a phase-II clinical trials in Alzheimer's disease released by Coya Therapeutics
- 19 Mar 2024 Coya Therapeutics completes the phase-II clinical trials in Alzheimer's disease in USA (SC)